The Delhi High Court has taken a firm stand by rejecting Novo Nordisk's plea to pause a prior ruling. This decision empowers Dr Reddy's Laboratories to manufacture and ship its Semaglutide drug to countries free from Novo Nordisk's patent. The court described Novo Nordisk's arguments as lacking strength, with the next hearing scheduled for January 15.

See Full Page